Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium

The current gold standard for prostate cancer treatment is androgen deprivation therapy and antiandrogenic agents. However, adverse cardiovascular events including heart failure can limit therapeutic use. Istaroxime, which combines Na(+)-K(+)-ATPase (NKA) inhibition with sarco/endoplasmic reticulum...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Wallner, Markus, Khafaga, Mounir, Kolesnik, Ewald, Vafiadis, Aris, Schwantzer, Gerold, Eaton, Deborah M., Curcic, Pero, Köstenberger, Martin, Knez, Igor, Rainer, Peter P., Pichler, Martin, Pieske, Burkert, Von Lewinski, Dirk
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2017
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564766/
https://ncbi.nlm.nih.gov/pubmed/28514771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17540
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk